INTRODUCTION
Malignant brain tumors cultivate a variety of mechanisms to escape local and systemic immunity. Current treatments are restricted to neurosurgical procedures, chemotherapy, and radiotherapy. [34] e major limitation to effective therapeutic strategies lies in the impermissibility of the blood-brain barrier, which blocks the access of targeted drugs into tumor sites. [15] For long, it was believed that the lack of lymphatic drainage and antigen-presenting cells protects brain tumors from immunity; however, preclinical and translational studies in the past decade changed the perception on the role of immune cells in brain tumors. [12, 32, 37] Brain tumor cells are equipped with the ability of secreting numerous chemokines, cytokines, and growth factors that stimulate the infiltration of various neural cells and a range of immune cells into the tumor. Altogether, these cells create a special niche called the tumor microenvironment, which is crucial for cancer proliferation, spread, and response to treatment. e tumor microenvironment has the ability of reprogramming attacking immune cells through local release of cytokines and chemokines, [17] which leads to protumor inflammatory or anti-inflammatory responses. Similar to other cancers, the brain tumor microenvironment has evolved multiple ways to inhibit the antitumor activity of immune cells. [29] Glioma research has shown that a strong link exists between the immune system response and disease progression. [18, 31, 35] Natural killer (NK) cells are large granular lymphocytes that play an important role in antitumor immunity. On activation, NK cells induce target cell apoptosis through contact-dependent cytotoxicity primarily mediated by perforin and granzyme B [7, 9, 25] and secretion of pro-inflammatory cytokines such as tumor necrosis factor-α and interferon-γ. [6, 27, 36] In brain tumors, NK cells have proven to be effective in in vitro [2, 4, 8] and in vivo [1, 16, 30] settings. ey can recognize and kill human glioblastoma cells that exhibit stem cell-like properties. [4, 8] erefore, in this paper, we explore the role of NK cells in the brain tumor microenvironment and discuss the challenges facing possible therapeutic regimens using NK cells against brain tumors.
NK CELLS AND THE BRAIN TUMOR MICROENVIRONMENT
NK cells constitute an integral part of the intratumoral immune cell population in the brain tumor microenvironment. Multiple studies have investigated NK cell numbers and activity in patients with brain tumors. Using suboptimal antibody techniques, Stevens et al. [33] showed that NK cells are present www.surgicalneurologyint.com
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in metastatic brain tumors and craniopharyngiomas. Yang et al. [38] added that NK cells frequently infiltrated glioblastomas. Domingues et al. [11] confirmed their presence in meningiomas. Current advancements and the development of more precise methods offer the opportunity to study better the infiltration of NK cells in various brain tumors.
e functioning of NK cells is often affected in patients with brain tumors due to the immunosuppressive factors released by tumor cells. Glioma cells, for example, highly express a special form of major histocompatibility complex Class I molecules, [23, 26] which act as ligands for inhibitory receptors expressed on NK cells [ Figure 1 ]. Böttcher et al. [5] reported that tumors that secrete inflammatory mediators like cyclooxygenases (COX) and prostaglandin E2 suppress NK cell antitumor activity. Interestingly, COX-deficient tumors were extensively infiltrated by dendritic cells. e authors further uncovered a role for NK cells in recruiting dendritic cells to the tumor microenvironment by releasing CCL5 and XCL1 chemokines. [5] is NK cellmediated activity governs dendritic cell antitumor function in various human cancers, like melanoma, breast cancer, lung cancer, and head and neck cancers. Amplifying the role of this axis was shown to impact survival positively. [5] Impaired immune function and increased anti-inflammatory molecules are common in patients with glioma. In patients with glioblastoma multiforme, Fadul et al. [13] observed a decrease in the number of NK cells in isolated tumor specimens after being treated with radiation and temozolomide. e NK cell frequency and cytotoxic activity were downregulated as a result of antiinflammatory molecules, like transforming growth factor-β (TGF-β). Moreover, the decrease in the level of expression of NK cell-activating receptor, NKG2D, in patients with glioblastoma further reflects the common immune evasion mechanisms exhibited by brain tumors. [22] 
NK CELL-BASED THERAPIES IN NEURO-ONCOLOGY
Although studies show that NK cells account for a minority of infiltrating leukocytes in brain tumors, [24] novel therapies based on increasing NK cell recruitment and function are emerging. e major challenge facing NK cell therapies in neuro-oncology [8] showed that NK cells can kill human glioblastoma cells that exhibit stem cell-like properties. Ishikawa et al. [21] demonstrated that pure autologous NK cells are safe and partially effective in patients with recurrent malignant gliomas; tumor regression was recorded in 4 of 9 patients. e partial efficacy of NK cells might be due to the tumor-induced immune suppression and immune escape mechanisms. A number of early phase trials are studying the dosage, safety, and side effects of NK cell therapy in the treatment of advanced cancers (NCT00823524 and NCT00909558). Choi et al. [10] reported that donor-derived NK cells are well tolerated at a median total dose of 2 × 10 8 cells/kg and can decrease the progression of acute leukemia.
In pediatric brain tumors, it has been suggested that NK cells may also be effective against medulloblastoma. A phase 1 clinical trial is currently undergoing whereby autologous expanded NK cells are injected into the brain of patients who have undergone resection of recurrent infratentorial tumors (NCT02271711). Phase 2 clinical trials are employing expanded autologous NK cells in combination with T cells to attack high-risk pediatric brain tumors (NCT01804634 and NCT02100891). It is believed that combination therapies involving NK cells might enhance the effectiveness and/or overcome brain tumor immune escape mechanisms. [14] While these early phase trials are vital to realize the optimal dose, safety, and efficacy of NK cell therapies, combination tactics are likely compulsory to fully reap the benefits of adoptive cell therapy. Potentiating the immunogenicity of the brain tumor microenvironment through immunotherapy may be necessary to fully exploit the effects of NK cell therapy. [28] Immunotherapy can counteract the tumor-induced immunosuppression and synergize with NK cell therapy for maximal therapeutic benefit. Furthermore, combination therapies involving immunotherapeutic agents and NK cells can be vital in overcoming resistance to immune checkpoint inhibitors in some cancers. It has been shown that PD-1/PD-L1 blockade elicits a strong NK cell response that is indispensable for the full therapeutic effect of immunotherapy. [20] Ultimately, this can increase the portion of patients that can benefit from immunotherapy.
Although NK cell-based therapy exhibits limited neurological toxicity, it can produce immune reactions, such as graft versus host syndrome. [19] Another major challenge for this therapy is its cost. Expanding NK cells is very expensive, particularly when many purification and stimulation steps are essential. [3] In addition, the lack of a common large-scale clinical grade expansion method that yields uniform products is a hurdle. Moreover, the variability in NK cell number, phenotype, genotype, and function from individual donors are all obstacles that need to be overcome if NK cell therapy ought to make an impact in neuro-oncology in the future. 
CONCLUSION

